Background/aim: To evaluate the detection rate for clinically-significant prostate cancer (PCa) of transperineal (TP) vs. transrectal (TR) multiparametric MRI/TRUS (magnetic resonance imaging/transrectal ultrasound) fusion targeted-biopsy.
Patients And Methods: From January 2016 to December 2016, 150 men underwent repeat saturation transperineal prostate biopsy (SPBx; median 30 cores) combined with targeted mpMRI/TRUS TR and TP fusion biopsies (4 cores for each procedure) of suspicious MRI lesions (PI-RADS 3/5).
Results: Overall, in 55/150 (36.6%) men a clinically-significant PCa was found and in 49 (89.1%) of them mpMRI was positive. SPBx, mpMRI/TRUS TR and TP fusion targeted-biopsy diagnosed 52 (94.5%), 43 (78.1%) and 49 (89.1%) PCa, respectively; TR fusion biopsy missed 8 (53.3%) while TP missed 2 (13.3%) cancers of the anterior zone.
Conclusion: Multiparametric MRI/TRUS TP in comparison to TR fusion biopsy detected a greater percentage of small but clinically significant PCa of the anterior zone (86.7% vs. 46.7%; p=0.0001).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.21873/anticanres.11695 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The presence of prostate MRI-visible lesions at follow-up biopsy as a risk factor for histopathological upgrading during active surveillance.
Abdom Radiol (NY)
March 2025
Universidade de São Paulo, São Paulo, Brazil.
Objective: To prospectively determine the ability of visible lesions on multiparametric MRI (PI-RADS 4-5) and commonly used biomarkers to predict disease upgrading on rebiopsy in men with low-risk prostate cancer (PCa) enrolled in active surveillance (AS).
Materials And Methods: For this prospective study, approved by the Institutional Review Board (IRB), we selected consecutive patients with low-risk, low-grade, and localized prostate cancer (PCa) from our active surveillance (AS) program, who were enrolled between March 2014 and December 2020. Patients who had undergone previous prostate surgery, hormonal treatment, had contraindications for mpMRI, or transrectal ultrasound-guided (TRUS) biopsy were excluded from this study.
Ultrasound and advanced imaging techniques in prostate cancer diagnosis: A comparative study of mpMRI, TRUS, and PET/CT.
J Xray Sci Technol
February 2025
Department of Medical Imaging Center, Central Hospital Afffliated to Shandong First Medical University, Jinan City, China.
Objective: This study aims to assess and compare the diagnostic performance of three advanced imaging modalities-multiparametric magnetic resonance imaging (mpMRI), transrectal ultrasound (TRUS), and positron emission tomography/computed tomography (PET/CT)-in detecting prostate cancer in patients with elevated PSA levels and abnormal DRE findings.
Methods: A retrospective analysis was conducted on 150 male patients aged 50-75 years with elevated PSA and abnormal DRE. The diagnostic accuracy of each modality was assessed through sensitivity, specificity, and the area under the curve (AUC) to compare performance in detecting clinically significant prostate cancer (Gleason score ≥ 7).
Is there a role of PSMA-PET in focal therapy planning and follow-up?
Prostate Cancer Prostatic Dis
February 2025
S.H.Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China.
Introduction: Focal therapy (FT) is a promising alternative to radical treatments for localized Prostate Cancer (PCa) in selected patients. However, it is not yet considered a standard treatment option, and there is currently no consensus on managing patients after FT. In this context, Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) may support multiparametric MRI (mpMRI) for both pre-operative planning and follow-up.
View Article and Find Full Text PDFPositive Predictive Value of High-Grade Prostate Imaging and Reporting Data System V2.1 Magnetic Resonance Imaging Findings for Prostate Cancer.
Ethiop J Health Sci
October 2024
Department of Radiology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.
Background: Prostate cancer is a leading cause of cancer-related mortality among men, second only to lung cancer. Prostate magnetic resonance imaging (MRI) utilizing the Prostate Imaging and Reporting Data System (PI-RADS) v2.1 scoring system effectively stratifies patients by risk and correlates significantly with histopathological outcomes.
View Article and Find Full Text PDFThe number of involved regions by prostate adenocarcinoma predicts histopathology concordance between radical prostatectomy specimens and MRI/ultrasound-fusion targeted prostate biopsy.
Front Oncol
December 2024
Department of Urology, Soroka University Medical Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er-Sheva, Israel.
Article Synopsis
- Using MRI-fusion guided prostate biopsy (PB) leads to better agreement with prostatectomy histopathology results compared to traditional 12-core TRUS biopsy, especially in patients with higher-risk prostate cancer.
- In a study involving 218 men diagnosed with prostate cancer, those who underwent MRI-fusion PB had a significantly higher concordance rate (73.1% vs. 42.9%) with the final pathology from surgery.
- The research highlighted that the number of cancer-involved regions in the prostate is an important factor influencing concordance, indicating that MRI-fusion techniques enhance diagnostic accuracy and treatment planning for patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!